Device Therapy in Patients with Heart Failure: Is Medication Use Optimized and Are We Targeting Those Patients Most Likely to Benefit?
Within 6 months of initiating GDMT, more than half of eligible patients with heart failure had been referred for a device, but one quarter were in the group least likely to benefit from a device, and not all were on optimal GDMT.
Authors
- Justin Adrian Ezekowitz (ORCID: https://orcid.org/0000-0002-2724-4086)
- Gavin Y. Oudit (ORCID: https://orcid.org/0000-0002-9154-9028)
- Derek S. Chew (ORCID: https://orcid.org/0000-0003-3539-7485)
- Robert Wannamaker
- Chandu Sadasivan (ORCID: https://orcid.org/0009-0007-4077-4261)
- Finlay A. McAlister (ORCID: https://orcid.org/0000-0001-7435-3341)
- Chen-Hsiang Ma (ORCID: https://orcid.org/0000-0002-0757-7609)
- Luke Gagnon
- Roopinder K. Sandhu (ORCID: https://orcid.org/0000-0002-2629-3476)
- Sheri L. Koshman (ORCID: https://orcid.org/0000-0001-9867-051X)
Institutions
- University of Alberta (CA)
- University of Calgary (CA)
Publication Details
- Journal
- CJC Open
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1016/j.cjco.2025.04.016
- Primary Topic
- Cardiac pacing and defibrillation studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Canada Research Chairs